Last reviewed · How we verify

NCT06587100: WATCH

Wearable Activity Tracking to Curb Hospitalizations

Recruiting now Last updated 17 April 2026
What this trial tests

trial testing Fitbit in Hematopoietic Neoplasm in 260 participants. Currently enrolling.

Timeline
7 April 2025
Primary endpoint
31 December 2027
31 December 2027

Quick facts

Lead sponsorUniversity of California, San Francisco
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment260
Start date7 April 2025
Primary completion31 December 2027
Estimated completion31 December 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Hematopoietic Neoplasm or Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to collect patient generated health data to predict the risk of patients needing emergency department visits or hospitalization before, during. and after receiving radiation therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Fitbit

Trials testing the same drug.

Other University of California, San Francisco trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06587100.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing